Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Results

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.47%

Catalyst Pharmaceuticals reported a strong EPS performance, exceeding expectations significantly. However, the stock reacted negatively, declining by 1.47%. This could indicate investor caution due to the lack of revenue guidance and uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.53	N/A	+110.32%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS performance, highlighting their commitment to long-term objectives. However, they did not provide specific guidance for future revenue.

We are pleased with our EPS results this quarter.

While we didn't provide specific revenue guidance, we remain focused on our strategic goals.

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.47%

Key numbers

Management commentary

Catalyst Pharmaceuticals, Inc.

More earnings this week

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.47%

Key numbers

Management commentary